COLL Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 32.59%. Collegium Pharmaceutical's return on equity of 31.53% beat Eli Lilly and's return on equity of 80.24%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 41.96%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 18.55%. Given that Collegium Pharmaceutical has higher upside potential than Eli Lilly and, analysts believe Collegium Pharmaceutical is more attractive than Eli Lilly and.

Collegium Pharmaceutical has a beta of 0.991, which suggesting that the stock is 0.9% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.63% to investors and pays a quarterly dividend of $1.50 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Collegium Pharmaceutical's net income of $12.5M is lower than Eli Lilly and's net income of $4.4B. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 16.21x while Eli Lilly and's PE ratio is 72.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.94x versus 17.11x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 2.31%. Collegium Pharmaceutical's return on equity of 31.53% beat Pfizer's return on equity of 8.91%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 41.96%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 22.34%. Given that Collegium Pharmaceutical has higher upside potential than Pfizer, analysts believe Collegium Pharmaceutical is more attractive than Pfizer.

Collegium Pharmaceutical has a beta of 0.991, which suggesting that the stock is 0.9% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.62% to investors and pays a quarterly dividend of $0.43 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are smaller than Pfizer quarterly revenues of $17.8B. Collegium Pharmaceutical's net income of $12.5M is lower than Pfizer's net income of $410M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 16.21x while Pfizer's PE ratio is 18.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.94x versus 2.29x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 8.8%. Collegium Pharmaceutical's return on equity of 31.53% beat Supernus Pharmaceuticals's return on equity of 7.61%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 41.96%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 17.4%. Given that Collegium Pharmaceutical has higher upside potential than Supernus Pharmaceuticals, analysts believe Collegium Pharmaceutical is more attractive than Supernus Pharmaceuticals.

Collegium Pharmaceutical has a beta of 0.991, which suggesting that the stock is 0.9% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.835, suggesting its less volatile than the S&P 500 by 16.47%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are larger than Supernus Pharmaceuticals quarterly revenues of $174.2M. Collegium Pharmaceutical's net income of $12.5M is lower than Supernus Pharmaceuticals's net income of $15.3M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 16.21x while Supernus Pharmaceuticals's PE ratio is 25.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.94x versus 2.79x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 31.35%. Collegium Pharmaceutical's return on equity of 31.53% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 41.96%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.19 which suggests that it could fall by -1.28%. Given that Collegium Pharmaceutical has higher upside potential than Vertex Pharmaceuticals, analysts believe Collegium Pharmaceutical is more attractive than Vertex Pharmaceuticals.

Collegium Pharmaceutical has a beta of 0.991, which suggesting that the stock is 0.9% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Collegium Pharmaceutical's net income of $12.5M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 16.21x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.94x versus 11.84x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.